Zeitschriftenaufsatz
|
2011
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Autor:in
Grebien, Florian; Hantschel, Oliver; Wojcik, John; Kaupe, Ines; Kovacic, Boris; Wyrzucki, Arkadiusz M; Gish, Gerald D; Cerny-Reiterer, Sabine; Koide, Akiko; Beug, Hartmut; Pawson, Tony; Valent, Peter; Koide, Shohei; Superti-Furga, Giulio;
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Journal
Schlagwörter
Amino Acid Sequence; Animals; Base Sequence; Benzamides; Cells, Cultured; Fusion Proteins, bcr-abl/antagonists & inhibitors*; Fusion Proteins, bcr-abl/chemistry*; Fusion Proteins, bcr-abl/metabolism; Humans; Imatinib Mesylate; Isoleucine/metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology*; Mice; Models, Molecular; Molecular Sequence Data; Piperazines/pharmacology; Protein Kinase Inhibitors/pharmacology; Protein-Tyrosine Kinases/antagonists & inhibitors*; Protein-Tyrosine Kinases/chemistry*; Protein-Tyrosine Kinases/metabolism; Pyrimidines/pharmacology; Signal Transduction; src Homology Domains;
Dokumententyp
Originalarbeit
ISSN/eISSN
0092-8674 -
10.1016/j.cell.2011.08.046
WoS ID
PubMed ID